HC Wainwright & Co. Reiterates Buy on Kala Bio, Maintains $15 Price Target

Kala Pharmaceuticals, Inc. +8.12%

Kala Pharmaceuticals, Inc.

KALA

6.79

+8.12%

HC Wainwright & Co. analyst Yi Chen reiterates Kala Bio (NASDAQ: KALA) with a Buy and maintains $15 price target.
Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via